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When asked to write a paper for the 50th anniversary issue of the JID,
two feelings immediately come to mind: to be very proud and
honored, but, on the other hand, quite depressed because of the
unexpected amount of work this task calls for. When this paper
happens to bear the title ‘‘Clinical research in the JID,’’ the extent of
depression starts rising exponentially with the broadness of the field as
well as its lack of definition. As an antidepressant procedure, the first
question to consider is then, what is clinical research?
CLINICAL RESEARCH
When asked this question what is clinical research, many people
would agree that it is difficult to define. This common feeling reflects
the fear of investigators, nowadays struggling for grants, to embark in
laborious clinical studies on humans with a low chance of significant
yield. Mouse strains and cultures of established cell lines are by far
more easy to handle and to render homogenous than a group of
patients. If hard to define, what do we expect from clinical research?
It should provide clinicians with facts and concepts readily usable for
diagnosing, understanding, and treating human diseases.
Recently, an interesting distribution of responsibility took place on
the Editorial board of the JID when section associate editors were
appointed. When considering the sections one may feel that clinical
research is what is not photobiology, cell biology, immunology,
pharmacology, carcinogenesis, biochemistry, biologic structure and
function, extra cellular matrix, or melanocyte biology.
Does this mean that clinical research has not had an important
place in this journal? In fact, out of 203 papers submitted during the
last few months, 19 were considered by the Chief Editor to fall into this
category, i.e., 9.3%, which represents a sizeable amount of papers.
The way of collecting data for this review was based on a
remarkable subjective method. The bound volumes of the JID, starting
with No 1, 1938 and ending with No 88, 1986, were looked over.
The title and abstract of each article were read, and if the paper was
considered of potential interest as a ‘‘clinical research paper,’’ it was
quoted. An attempt was made to scan no more than 5 years per week
when the JID comprised only one volume per year and five volumes
when the Journal increased to two volumes per year.
Criteria for selecting an original paper, thus excluding review
papers, were severalfold. One common criterion was that the message
either still remains valid today or raised a controversy when it was
written that suggested further studies. Other criteria were as follows:
(1) first report on a new treatment, (2) particular studies done on
humans, (3) first description of a technique on humans that allowed
measurements of a function of the skin, (4) new clinical concepts or
‘‘new’’ diseases, or (5) studies on the pathogenesis of skin diseases.
This, by no means, implies that papers not falling into these categories
have no clinical impact. It is in fact my feeling that, say, the study
of ‘‘Epidermal growth in Bottlenose Dolphin (JID 85:60–63, 1985) may
ultimately prove to bring important insight to the clinician dealing with
a psoriatic patient. Moreover, many papers of direct potential
importance for the clinician could not be included because
they clearly pertain to pharmacology, immunology, genetics, etc.
These topics are covered in other sections of this anniversary issue.
Finally, due to my personal interest in this field, most if not all the
papers dealing with vitamin A and retinoids were quoted.
All this resulted in the ‘‘selection’’ of 190 papers, some of which
will be discussed in the following sections. Finally, the subjective
nature of this method of selection was compared to the list of the 200
top cited articles published in this issue.
Apologies Many important reports dealing with clinical research
have evidently been missed. It is hoped that the authors of these papers
will understand.
Table I shows the number of papers selected through this subjective
process. Twenty-one percent were subsequently found to be among
the 200 top cited JID papers in the ISI report. If the papers dealing
with retinoids are not included, the percentage raises to 26%. Because
it is generally accepted that the citation index rate does not necessarily
correlate with the ‘‘clinical usefulness’’ of a given paper, it was
thought that the subjective process of selection might have some
significance.
SIGNIFICANT (FIRST) PAPERS ON THERAPY (TABLE II)
‘‘During the past few years a new group of so called antihistaminic
agents has been developed and studied in Europe and in the United
States,’’ wrote R. Baer and M.B. Sulzberger in 1946 as the first
sentence of a paper on the use of pyribenzamine [1] (Table II). Because
they did not quote any other previous paper, this might have been the
first on the use of systemic antihistaminics in dermatology. They
treated 56 patients and found pyribenzamine to be of ‘‘therapeutical
value’’ in about one half of chronic urticaria, without effect in atopic
dermatitis, and sometimes of value in some cases of ‘‘essential
pruritus.’’ The natural outgrowth of systemic antihistamines was the
use of topical preparations. A paper on this topic was published the
following year (1947) by D.J. Perry [2]. He observed that ‘‘local
application of 2% Benadryl ointment is not followed by sufficient
absorption (if any) to decrease the experimentally produced histamine
wheals.’’ He then treated 22 patients with various pruritic dermatoses;
moderate relief of itching was obtained in six and excellent relief in
two. In 50% of these responders, the ointment base alone was as
active as the drug. The only explanation considered for this was a lack
of penetration. Dermatologists have since learned that when a drug is
found to be active systemically, the topical route is frequently
disappointing for many reasons other than just absorption. It is
interesting that a number of topical antihistamines are still marketed
and sold. The story of topical antibiotics [3,4] was more successful.
Because penicillin was said to be unstable and induced frequent
sensitization (M.B. Sulzberger, Ref 3) new compounds that would only
be used topically and proved not to be sensitizing were searched for.
Gramicidin was one of these agents, first reported by Anderson in
1947 [3], and bacitracin was used in the treatment of 155 patients by
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Miller et al in 1948 [4]. Reading the discussion that follows Anderson’s
paper is fascinating. F.D. Wiedman proposed (p. 32) ‘‘we should
remember that we may do better than confine ourselves to the extracts
of these microorganisms (Gramicidin was extracted from a bacteria);
we can employ the organisms themselves in the living state.’’ In some
ways this was conceptually the root of the concept of bacterial
interference (suppression of bacterial growth by other bacteria), which
unfortunately has had little impact on dermatology. Sensitization was
a concern, but the acceptable rates were quite different from those
considered nowadays. Miller [4] found 1% of the cases developing
contact dermatitis to be ‘‘a low sensitizing potential.’’
Wooldridge [5] reported on what seems to be the first use of the
gamma isomer of hexachlorocyclohexane, the popular Lindane in the
treatment of scabies. He treated 72 patients with a 1% vanishing
cream applied once every 24 h. He found that 95% of the patients
were cured and noted ‘‘it is doubtful if the rate of five percent relapses
could be significantly lowered, no matter how intelligent and
cooperant a group of patients might be.’’ He also stated that ‘‘There
are as yet no reported instances of toxic symptoms in many’’ Forty
years later, the patients are supposed to be as intelligent and
cooperant, the drug is widely used, and the toxicity is still a matter
of debate. At that time, the JID was accepting case reports. Tyson [6]
found that a patient given gelatin internally ‘‘in the hope of relieving
her muscular weakness’’ had her ‘‘fragile’’ nails returned to normal.
He then ‘‘treated’’ twelve additional subjects (11 women, 1 man) with
7 g of commercial gelatin once a day for up to 3 months; there were 10
success. Some still use gelatin for brittle nails, but little insight on how
it could bring improvement has been provided since this report.
Melton and Shelley [7] studied the effect of 54 topical preparations
on the inhibition of histamme induced pruritus. Looking at the list of
the compounds used in 1950, one may appreciate that very little
progress has been made since. Interestingly, none of the compounds
had a significant effect. Although the authors conclude that their study
provided ‘‘no experimental evidence to indicate usefulness of local
antipruritic medicaments when applied to skin of normal perme-
ability,’’ many are still sold today, including Menthol, Calamine
lotion, antihistamines, and topical anesthetics. It would be interesting
to know what Professor Shelley is using nowadays.
In a paper entitled ‘‘The effects of penicillin on certain hitherto
incurable dermatoses’’ V.H. Witten [8] confirmed the previous
observations of European investigators, including N. Thyresson, that
acrodermatitis atrophicans chronica improved with penicillin therapy,
but noted that established atrophy was not improved. He quoted a
personal discussion with his chairman, Professor M.B. Sulzberger:
‘‘While by no means this was conclusive evidence, it once more
directs attention to the possibility of treponemes playing some part in
the pathogenesis.’’ We know 40 years later that the ‘‘treponemes’’
were spirochetes of the genus Borellia.
M.B. Sulzberger [9] reported on the effect of ACTH, known as
Armour at the time, in 44 patients with 19 different dermatologic
conditions, and likewise studied various physiologic functions of the
skin before, during, and after administration of ACTH. There is not a
single message in Sulzberger’s long paper that well reflects the
excitment of dermatologists dealing with a potent systemic anti-
inflammatory drug for the first time. In the same year Brunner et al [10]
reviewed the cutaneous side-effects of ACTH and cortisone therapy,
and one of the interesting conclusions was that their observations
confirmed the ‘‘causative importance of steroid hormones endogen-
ously produced in acne vulgaris andy seborrheic dermatitis.’’ ‘‘It has
been the experience of most investigators that the topical use of
cortisone acetate ointment is without value in the treatment of diseases
of the skin,’’ said M.B. Sulzberger [11] in the first sentence of a short
report on the use of ‘‘compound F’’ (17 hydroxycorticosterone 21
acetate). He treated 19 patients and observed slight improvement in
seven, mostly atopic dermatitis, whereas DLE, pemphigus vulgaris,
and alopecia, of course, did not respond. It seems this is the first
observation on the clinical efficacy of topical steroids; it was published
Table I.
Subject Section
Clinical
Research
Papers Selected
for This Reviewa
Number and
(%) of These
in the 200
Cited Top
Therapy 33 4 (12%)
Peculiar experiments in humans 13 4 (30%)
New techniques 20 13 (65%)
New clinical concepts or new diseases 22 4 (18%)
Pathophysiology of some skin diseases 40 8 (20%)
Total 128 33 (26%)
Rtetinoidsb 61 3 (5%)
aSelected by a subjective method (see text). Not all are commented upon
in this review.
bAlmost all papers are quoted, including papers not strictly on clinical
research.
Table II. Significant Papers on Therapy
Reference
1. Antihistaminics. Systemic 1
2. Antihistaminics. Topical 2
3. Topical antibiotics 3,4
4. HCH in the treatment of scabies 5
5. Gelatin for fragile nails 6
6. Study on 54 topical antipruritic agents 7
7. Penicillin for acrodermatitis chronica antrophicans 8
8. Systemic ACTH and cortisone treatment 9,10
9. Topical hydrocortisone 11a
10. Antimalarial treatment of lupus erythematosus and
light sensitive eruptions
12–15
11. Systemic antibiotic therapy for acne vulgaris 16
12. Sulfones for dermatitis herpetiformis 17
13. Benzophenones as sunscreens 18
14. Intralesional triamcinolone 19
15. Increased absorption of griseofulvin by fat meal 20a
16. Laser used on skin 21
17. Amount of topical preparation required for total and partial
body inunction
22
18. Controlled study of the charming of warts 24
19. Topical 5-fluorouracile for basal cell carcinomas 25,26
20. Beta carotene does not prvent sunburn 27
21. Multicenter US PUVA therapy study in psoriasis 28a
22. Association of oral retinoids with PUVA 29a
23. Topical Capsaicin 30
24. Naloxone has antipruritic effect 31
25. What about azelaic acid? 32,33
aQuoted in the 200 top cited papers of the JID.
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in the section ‘‘preliminary and short reports’’ but is still among the
200 top cited papers of the Journal (Fig 1).
Although the first mention that Mepacrine might be of benefit in
lupus erythematosus was reported in 1941 by Popoff et al (cited in
Ref 14) and subsequently confirmed by Page in the Lancet in 1951
(cited in Ref 14), three papers [12–14] appeared in the December 1952
issue of the JID. At that time, one could start a paper by stating, like
Cramer and Lewis [12], that ‘‘no remedy for the treatment of chronic
DLE has proved invariably helpful.’’
‘‘New and superior therapy for LE appear periodically in the
dermatologic literature; they are then evaluated with hopeful
scepticism by the profession,’’ said Sawicky et al in Ref 13. However,
of the 48 patients in the three studies, there were only six failures.
Thirty-five years later there is no longer skepticism! Knox et al [15]
later reported on the improvement by Mepacrine of cases of prurigo
aestivalis and other light sensitive eruptions. He took advantage of this
to propose that the drug might act in both LE and other light sensitive
eruptions via a light screening effect rather than an antiplasrnodial
or infectious mechanism.
‘‘The lesions of acne have often been found to harbor coryne-
bacterium acnesy it was felt that if the corynebacterium does
contribute to the pathogenesis of acne vulgaris, then erythromycin
might be of definite benefit’’ stated Van de Erve in 1954 [16]. He
treated 60 cases of acne vulgaris and observed excellent control of
pustules but no effect on the ‘‘sebaceous secretion.’’ Because the
author did not quote any previous report, it seems that, unless the
reviewers and editors did not do their job, this might be the first report
on the therapy of acne with systemic antibiotic.
Sometimes the JID may have served as a tool to disseminate
concepts that were not accepted even if previously published in the
Archives of Dermatology. Cornblett complained [17] that ‘‘not
withstanding good results shown in his previous study on five
patients’’ treated with Dapsone for dermatitis herpetiformis, ‘‘this
form of therapy did not become popular.’’ He reported on 14 more
patients. His paper is written like an editorial or a comment rather than
a scientific paper. Despite its historical significance this might explain
why it is not quoted in the 200 top cited papers of the JID.
In 1957, a new group of ultraviolet light absorbers, benzophe-
nones, was presented [18] and compared to previously used sun-
screening agents such as PABA and tannic acid. The paper, as many at
that time, is followed by a discussion in which the author was asked by
Dr Kestin and Dr Baer about the safety and allergenic potential of
benzophenones. The author prudently answered ‘‘time alone will tell
the clinical application of the benzophenones.’’ Time told us, it’s O.K.
‘‘The physician who necessarily regards the disappearance of a
lesion as certain evidence of cure would indeed be naive. However,
the patient whose skin lesion has for months resisted the expert
therapy of dermatologist is certainly impressed if, after a single
injection, the lesion disappears within a few days’’ [19]. There were 90
patients in this trial and the injection was a sterile aqueous solution
of triamcinolone acetonide that was recently made available for
investigative use. This historical paper on intralesional steroid therapy
reflects the excitement not only of the patients but also the author, who
wrote that he felt the data ‘‘should be reported immediately!’’
In 1961 griseofulvin was the only systemic antimycotic drug to be
used for dermatophytic infections, and many cases were found
unresponsive. In a well-designed study, R.G. Crounse [20] found
that a high fat meal nearly doubled the blood levels of griseofulvin
following a test dose. In order to avoid the patients needing this
drug putting on weight, the industry has now provided us with new
formulations that render this important finding less applicable.
The first paper on laser use on human skin appears to be by
Goldman et al in 1963 [21]. They used a ruby laser with an output of
more than 5 joules, and their observations were not dramatic.
How many grams of topical preparation are needed for total body
inunction? Many more when a ‘‘superficially instructed individual’’
does it, as compared to a ‘‘trained operator’’ with a range from 7.7 to
114.8 g [22]. This important and clinically relevant study has probably
received little attention because it is not in the 200 top cited papers,
but it contains pertinent observations that seem to be still usable today,
especially for nurses.
In his book The Medusa and the Snail [23] Lewis Thomas wrote
‘‘Warts are wonderful structuresy They can be made to go away by
something that can only be called thinking, or something like
thinking.’’ He probably did not read the JID paper on ‘‘the charming
of warts’’ [24]. This was a controlled study using two procedures: a
slight electric shock or a simulated x-ray exposure. The conclusion
was that the suggestion, or charming, does not succeed when
experimentally controlled.
What appear to be the first controlled double-blind studies on the
effect of topical 5-fluorouracil on basal cell carcinomas were
published in 1965 [25,26]. Topical 5-fluorouracil proved to be
superior to other topically applied anti-tumor agents such as
Figure 1. This report by Sulzberger and Witten (J Invest Dermatol
19:101–102, 1952) was a harbinger of great things to come, the effect of
potent topical steroids on the practice of dermatology. It is number 106 of the
200 most cited papers in the JID.
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Actinomycin D, Nitrogen mustard, Methotrexate, and 5-Mercaptour-
acile. We later learned that basal cell carcinomas are best treated by
excision or radiotherapy, but 5-fluorouracil is still widely used for
actinic keratosis.
Important studies from the Boston group often first appeared in the
New England Journal of Medicine, but further analyses were usually
published in the JID. Because they had recently found that feeding
beta-carotene ameliorates the photosensitivity of patients with
erythropoietic protoporphyria, the same group of investigators wanted
to know whether beta-carotene could serve as a photoprotective agent
for sunburn [27]. The answer was no, and we still await for a systemic
sun protective agent.
The multicenter trial on PUVA of Melski et al [28] appeared in the
JID in 1977, three years after the first report in the New England
Journal of Medicine. This is a key paper on 1308 U.S. patients, which
is third on the list of the 200 top cited papers in the JID.
That PUVA might be potentiated by oral retinoids was first
demonstrated by Fritsch et al [29]. Although this was not a double
blind study, it drastically modified the use of both retinoids and PUVA
in the treatment of psoriatic patients.
Although the drug is only used, so far, for zoster pain, Capsaicin
might have a brighter future. Bernstein et al [30] reported in 1981 that
topical application of this pugent principle of hot pepper did inhibit
histamine-induced axon-reflex vasodilatation, possibly by depleting
substance P from local sensory nerve terminals. Also in the line of
‘‘neurodermatology’’ is the report by the same author [31] that
Naloxone, an opiate antagonist, has an antipruritic effect. So far this
important observation has no therapeutical application because the
opiate antagonists are not easy to use in practice.
This section on ‘‘significant papers on therapy’’ will be closed not
by refering to a paper but rather to a letter to the editor and its reply
[32,33]. Both are on azelaic acid and its effect as a depigmenting and
chemotherapeutic agent. For the reader who is not an expert in the field,
the Letter to the Editor is sometimes as informative as the original papers,
because the controversy is not dampened by the review process!
PECULIAR EXPERIMENTS IN HUMANS
It is interesting that the first study selected on the experimental
induction of photoallergy to sulfanilamide [34] was done on
volunteers ‘‘including myself’’ wrote the author. Not all the studies
in humans, subsequently reported, included such an ‘‘ethical control.’’
The paper by W.B. Shelley and Horwath on experimental miliaria in
humans [35] is one of the many studies dealing with sweat disorders
that were published in the JID during and just after WWII. The interest
in this topic was most probably due to exposure of U.S. soldiers to
tropical climates.
The other studies selected for this section fall into three categories
(1) the induction of either sensitization, flare, or tolerance to simple
chemicals, (2) the reproduction of superficial bacterial or fungal
infections, and (3) the exposure of human skin to newly purified
mediators of inflammation.
Sensitization to Simple Chemicals In the study by Sidi [36]
patients with topical sensitization to sulfonamides or anesthetics were
exposed to ‘‘oral or injected challenge’’ to both drugs in order to
demonstrate systemic cross reactivity amongst the ‘‘para group.’’ They
concluded that ‘‘cutaneous sensitization can bring about systemic
sensitization and occasionally serious accidents, which can be caused
by the agent that has sensitized the patient as well as by an entire
group of chemically related substances.’’
Passive transfer of contact hypersensitivity in humans had been
unsuccessfully tried several times with the use of blister fluid or white
blood cell suspension, etc. In 1957 Epstein and Kligman [37] used
concentrated leucocytes obtained from venous blood of sensitized
donors. They were able to transfer sensitization to three contact
allergens in males aged 20–45 years, and to one contact allergen in
one out of six children.
R. Baer was a pioneer in contact sensitivity. When nitrogen
mustard was found to be topically effective in some cases of psoriasis,
it became evident that it was also a potent contact allergen. Because
the drug ‘‘fulfilled the requirement for a trial of prevention of allergic
contact sensitization in man’’ (i.e., had been used intravenously for
many years), the trial was performed [38]. Unfortunately, it was a
failure, which was interpreted as being possibly due to the schedule
used. Subsequent studies did not establish a proper tolerogenic
schedule that would prevent sensitization in all patients. This well
demonstrates how difficult relevant clinical research is in humans.
Experimental Infections of Human Skin An impressive study, in
many respects, was that of Vilanova et al [39], who infected human
nails with fungi such as T. schoenleini, rosaceum, rubrum, etc.
Fortunately the success in inducing onychomycosis was only 24%,
and this persisted for 6 months at most. More recently [40], 27
psoriatic patients were inoculated on psoriatic plaques with either
Trichophyton rubrum or Mentagrophytes; 16 developed infection with
a better score for Trichophyton rubrum. This study demonstrated that
psoriatic scales are not repellent for these two fungi as previously
thought, and that a psoriatic patient, especially when under occlusive
topical steroid therapy, may develop tinea ‘‘incognita.’’ Tinea
versicolor was experimentally reproduced in humans [41,42]. The
paper by Burke [41] is among the 200 top cited papers in the JID,
probably because it provided not only evidence for experimental
infection, which was achieved in several instances, but also because it
related it to underlying systemic disease such as Cushing’s syndrome,
systemic steroid therapy, etc. It still stands as one of the key references
in the field.
Bacteria were also inoculated to human skin, but it was not easily
infected. Duncan et al [43] had to (i) apply Staphyloccoci and
Streptococci in the form of an overnight broth culture, (ii) stab through
the drop of inoculate with a blood lancet, and (iii) cover the site with
non-porous plastic tape. The highest rate of successful infection was
38% on the legs and only 13% on the arms. Inoculation on normal
skin produced only one infection in 78 inoculations. More recently,
Leyden et al [44] confirmed and extended these observations and
wrote ‘‘we have demonstrated for the first time that localized self
healing infections can be regularly produced with several strains of
streptococci.’’ Normal intact skin was never colonized or infected,
whereas inoculation on skm damaged by superficial scarification
resulted in localized infections when the wound was covered by an
impermeable plastic film. Nice color photographs illustrate the clinical
evolution of the lesions in this paper. They should be used when
teaching on impetigo!
Mediators of Inflammation When a mediator of inflammation
becomes available in sufficiently purified form, the natural tendency of
the experimental dermatologist is to either apply it topically or inject it
intradermally in human skin. There were numerous studies on
histamine that, for lack of space, will not be commented upon here.
Rather, two studies on leukotriene B4 were selected because they well
illustrate the importance of the route of administration. Soter et al [45]
injected leukotriene B4 and noted erythema and wheal formation with
dermal infiltrate of neutrophils on histology. When Camp et al [46]
applied leukotriene B4 topically, they induced intra-epidermal
neutrophilic abcesses. Unfortunately, they did not induce psoriatic
changes (Fig 2).
NEW TECHNIQUES FOR USE ON HUMAN SKIN WITH
SIGNIFICANT IMPACT ON EXPERIMENTAL
DERMATOLOGY AND DIAGNOSIS OF SKIN DISEASES
This is probably the section that groups the major contributions of
investigative dermatology to clinical practice. Interestingly, 65% of the
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papers selected for this section are in the list of the 200 top cited
papers in the JID. Most of these papers are commented on in other
articles in this issue; however, it seemed relevant to list them as a
perspective (Table III).
This list includes Pinkus’ historical papers [47,48] on the strip
method of removing horny layers. The story starts [47] with an
illuminating sentence: ‘‘It occurred to me that Wolf’s method might be
valuable in many other ways—(than just recovering stratum corneum
for examination)—for gaining information not only about the horny
layer but about the entire epidermis.’’ It ends [48] with another key
comment: ‘‘Loss of keratinized cells is believed to be the primary
stimulus of epidermal proliferation.’’
The paper by Van Scott et al [49] describes in detail the method for
examining hair roots, later called trichogramm. As a first application it
establishes that the hair fall out induced by a high dose of
methotrexate therapy is anagen effluvium.
Two key papers on the biology of sebaceous glands and the way of
measuring sebum excretion, one by Kligman and Shelly [50], the other
by Strauss and Pocchi [51], are in the 200 top cited papers in the JID. It
seems fair to include with these the paper published 10 years earlier by
Jones et al [52], because it appears to have paved the way for the latter
studies.
In 1963 Burnham et al [53] made the first report on the use of the
direct immunofluorescent (so written) method in skin lesions of lupus
erythematosus, ‘‘eczema solare,’’ psoriasis, seborrheic dermatitis and
mycosis fungoides. The ‘‘lupus band’’ was detected in the nine
patients with LE, six systemic and three chronic. This was not the first
attempt to detect immunoreactants in skin lesions with this method.
Burnham et al even quote two previous studies published 1 year
before in the Archives of Dermatology, where, unfortunately for the
investigators, lupus erythematosus was not analyzed.
The paper by Weinstein and Van Scott [54] on the autoradio-
graphic analysis of turnover time after dermal injection of tritiated
thymidine provided direct information on the kinetics of psoriatic
epidermis as compared to normal. It established that turnover time in
psoriasis was about 2 d versus 13 in normal.
The suction blister method is now widely used in investigative
dermatology. What seems to be the first report on this phenomenon
appeared in the JID in 1950 [55], but the method was properly
described by Kiistala and Mustakallio in the JID (Fig 3) in 1967 and
1968 [56,57], three years after their first paper in the Lancet (cited in
Ref 57).
Many significant papers on immunofluorescence appeared from
the late 1960s to the early 1980s. Three have been selected for this
review: (i) the report by Chorzelski et al [58] establishing the direct
immunofluorescent pattern of dermatitis herpetiformis and adding a
further strong criterion for its distinction from bullous pemphigoid; (ii)
the description by Michel et al [59] of a solution that provides
Figure 2. Topical application of leukotriene B4 produces intraepidermal
abcesses in normal skin, but not the full clinical and histologic picture of
psoriasis. (From Camp R et al: J Invest Dermatol 82:202–204, 1984)
Table III. New Techniques for Experimentation and
Diagnosis
Reference
1. Examination of the epidermis by the strip method 47a,48a
2. Method for examining hair roots (trichogramme) 49a
3. Measuring sebum excretion and its significance 50a,51a,52
4. Lupus band test. (Direct immunofluorescence on
lesional skin)
53a
5. Autoradiographic analysis of turn over in psoriasis 54a
6. Suction blister method 55,56a,57a
7. IgA deposits in dermatitis herpetiformis 58a
8. Fixative solution for the transport of specimens for
immunofluorescence
59a
9. Sodium chloride. Separated skin for indirect
immunofluorescence
60
10. Immunoelectron microscopy of bullous pemphigoid 61,62a
11. Identification of T and B cells by the rosette method 63a
12. Monoclonal antibodies for immunohistochemistry and
Western Blotsb
64,65
13. Western Blot analysis of skin extract (cited on this page)
14. Measurement of cutaneous blood flow 66,67
aQuoted in the 200 top cited papers in the JID.
bExamples.
Figure 3. Proper demonstration of the suction blister technique by Kiistala (J
Invest Dermatol 50:129–137, 1968).
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adequate preservation of tissue fixed immunoglobulins in skin biopsies
(this allowed broadening the use of direct immunofluorescence to
private offices); and (iii) a much more recent paper by Gammon et al
[60] on indirect immunofluorescence on 1.0M sodium chloride-
separated skin (this technique allows differentiating anti-lamina lucida
and anti-sublamina densa antibodies without the use of electron
microscopy, i.e., bullous pemphigoid from epidermolysis bullosa
acquisita). This paper well illustrates how basic research on the
biology of the dermo-epidermal junction might ultimately yield a
simple yet useful diagnostic test.
Next, the period of immunoelectron microscopy and that of new
tools for characterizing cell subpopulations in the skin. Two important
papers on immunoelectron microscopy of bullous pemphigoid were
published in 1975, both demonstrating the localization of the IgG
deposits within the lamina lucida [61,62]. The era of identifying cell
subsets in the skin started with the use of the rosette technique [63].
The conclusion of the paper was ‘‘it is therefore possible to distinguish
between B cells, T cells and histiocytes in skin lesions.’’ This seems so
evident now that one has to remember the difficulties of playing with
the rosette technique on histologic slides in vitro. Then came the
monoclonal antibodies and all the journals were loaded with papers
on their use. Identifying cell subsets became possible not only within
lymphomonocytic infiltrates but also within epithelial populations.
These tools are now indispensable for the proper identification of
many skin lesions and tumors. The paper by Moll and Moll [64]
illustrates, as an example, what these new technical tools do bring to
clinical research. By using both immunohistochemistry and Western
Blot techniques they analyzed the cytoskeleton of extramammary
Paget’s disease and showed that the keratin pattern of Paget’s cells is
identical to that of the secretory, but not the ductal, cells of both
apocrine and eccrine glands. Another example is the use of
monoclonal antibody in the prenatal diagnosis of dystrophic
epidermolysis bullosa, as recently shown by Eady et al [65].
The importance of Western Blot analysis in clinical dermatology is
just being appreciated; the reader will find more details in the paper by
Krueger and Stingl in this issue.
Although the author of this review is not familiar with these
techniques, measurement of cutaneous blood flow seems to have an
important future. What appears to be the first paper on the use of laser
doppler for the measurement of cutaneous blood flow was published
in 1977 [66]. Since then, there have been many papers on this device,
but other techniques, such as the 133Xenon washout method, are also
currently used. A recent paper on this topic [67] indicated that the high
cutaneous blood flow in lesional psoriatic skin is not due to a
maximally passively dilated vascular bed and that the Woronoff ring
cannot be ascribed to vasoconstriction.
‘‘NEW DISEASES’’ OR NEW ASPECTS OF DISEASES
REPORTED IN THE JOURNAL OF INVESTIGATIVE
DERMATOLOGY
Unless strong errors were made in the method of scanning the JID
since 1938, it appears that very few ‘‘new diseases’’ or new aspects of
diseases have been reported in it. This is most probably due to the fact
that ‘‘new diseases’’ are most often established initially on clinical and
histologic grounds, and are therefore published in clinically oriented
journals. The papers that could be included under this heading are as
follows: (i) the observation by Sagher et al [68] that bone changes may
be associated with urticaria pigmentosa, which was considered as
‘‘one of the pure dermatoses’’ 1952; (ii) the report by Convit et al [69]
of Erythema dyschronicum perstans, ‘‘a hitherto undescribed skin
disease’’ (they described five patients and suggested two names
‘‘erythema chronicum figuratum melanodermicum’’ or ‘‘erythema
dyschronicum perstans,’’ which was finally adopted for being simpler
and, as stated the authors, suggested by Sulzberger); and (iii) the report
by Soter et al [70] on the syndrome urticaria arthralgia and
hypocomplementemia, which has been previously put forward by
McDuffie (cited in Ref 70). It is interesting to note that up to volume
87, very few (I only found 3) papers on AIDS have been published in
the JID.
PATHOPHYSIOLOGY OF SKIN DISEASES
Bacterial and Fungal Infections Besides the studies implying the
inoculation in vivo in humans, which were dealt with in Section III, a
number of significant papers on this topic appeared in the JID.
‘‘Erythrasma is a bacterial infection of the skin,’’ reported Sarkany
et al [71]. The observations satisfied the Koch’s postulates, and further,
the disease was shown to be dramatically responsive to systemic
erythromycin.
Groupe A streptococcal infections are often associated with flares
of guttate psoriasis; this led the group of K.D. Wuepper to suspect that
certain strains of streptococci might produce a substance which could
influence keratinocytes to undergo DNA synthesis and cell division.
They purified a factor of 29 000 D from group A type 12 strain NY5
which increased mitosis in the rabbit skin in vivo as well as the uptake
of 3H thymidine in human lymphocytes [72,73].
Selective bacterial adherence is a first step in the infection of a host
cell. Because staphylococcus aureus is readily isolated from patients
with atopic dermatitis and somewhat less so from those suffering
psoriasis, Bibel et al [74] considered increased adherence as a possible
cause of colonization. They made two important observations: (1) the
enhanced binding of staphylococcus aureus on atopic dermatitis
epithelial cells as compared to psoriatic and normal cells, and (2) the
fact that the degree of adherence was related to the progress of
keratinization; the fully keratinized cells carried twice as many
staphylococci as the upper level granular cells, which in turn bound
twice as many bacteria as the cells of lower layers. We are all waiting
for something that would compete with this adherence in atopic
dermatitis skin!
Similar studies on adherence to corneocytes were made with six
species of Candida by Ray et al [75]. They found that the species of
Candida that possess in vitro capability for adherence to epidermal
corneocytes and mucosal epithelial cells are the same species (notably
Candida albicans) associated with colonization and infection. They
further observed that fresh serum, possibly through the deposition of
complement component onto yeast cell surface, may exert a
protective effect by inhibiting Candida adherence to epithelial cells.
Ray and Wuepper [76] suggested that accumulation of neutrophilic
granulocytes within the epidermis and beneath the stratum corneum in
cutaneous candidiasis was due to activation by Candida alhicans of
the alternative pathway of complement generating chemotatic
factors.
There is considerable evidence that Pityrosporum orbiculare, an
almost ubiquitous skin commensal, is capable of transition to a hyphal
phase Pityrosporum furfur (Malassez), the cause of pityriasis versicolor.
Because a source of lipid is essential for growth, Catterall et al [77]
considered that pityrosporum orbiculare must inevitably possess an
enzyme capable of utilizing fats. They found that, in vivo, Pityrospor-
um furfur did not show surface lipase activity and concluded that skin
surface lipids are not critical for the pathogenesis of pityriasis
versicolor. Host susceptibility factors for this disease are still to be
clearly identified for preventing relapses and sparing tons of
lmidazoles!
The lipolytic activity that liberates free fatty acids from sebaceous
triglycerides is derived from corynehacterium acnes. This important
statement was derived from the observation by Marples et al [78] that
systemic tetracyclines therapy, which does not affect the other
microorganisms (i.e., coagulase negative cocci and Pityrosporum),
induces a reduction of free fatty acids.
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Observations on Some Commonplace Skin Conditions Many
papers addressing the pathophysiology of common benign skin
diseases that populate the daily clinic of the practicing dermatologist
were published in the JID. They provided interesting observations,
many of which should have therapeutical implications, and, at any
rate, should give the clinician the possibility of thinking on
‘‘mechanism,’’ even when confronted with commonplace skin
conditions. The following have been chosen as examples.
‘‘Milia are not retention cysts’’ claimed Epstein and Kligman [79],
thus correcting the ‘‘fallacy almost universally held’’ before their paper
was published in 1956. They studied serial sections of several sources,
including autotransplants of cutaneous tissues, and put forward the
concept that milia should represent a ‘‘simple keratinizing type of
benign tumor arising from equipotential cells, anywhere in the
cutaneous epithelial system.’’
The essential factor in rosacea is recurrent oedema induced by
various factors, most notably recurrent flushing [80]. Because it was
widely held that coffee provoked flushing in patients with rosacea,
Wilkin [80] wondered if its proscription and its substitution by
‘‘decaffeinated coffee’’ as ‘‘often suggested in major textbooks’’ were
justified. He measured the malar thermal circulation index and malar
skin temperature and found hot coffee, but not cold coffee nor
caffeine, to be responsible for flushing in rosacea patients. ‘‘The
probable mechanism by which ingested heat leads to the flushing
reaction is based on a counter-current heat exchange at the level of the
internal jugular vein and common carotid artery, and subsequently a
central thermoregulatory reflex’’ he concluded. A nice piece of
clinical research!
‘‘Although callosities of the plantar skin are common and often
disabling, little is known of their pathology or the reasons for their
persistance’’ stated Marks et al [81]. They found increased thymidine
autoradiographic labeling indexes in callosities as well as abnormal-
ities in corneocytes, such as decreased density and apparent reduced
shedding (as shown by the dansyl chloride test). So far these studies
have not provided informations on how to prevent callosities and how
to better treat them. No doubt, the Welsh investigators will tell us more
in the future!
Is circumscribed sebaceous gland hyperplasia often found in the
face of adults and aged because of increased proliferation of sebo-
cytes? The answer is no, as shown by a study by Lunderschmidt and
Plewig [82]. They found slowed down transit and turnover time as well
as decreased labeling indices, as compared with the uninvolved
sebaceous glands of the same ederly subjects. Should we consider
another denomination for that condition, such as ‘‘retentional
sebaceous hypertrophy’’?
Skin limited amyloidoses is another commonplace situation in
practice. Hashimoto has been instrumental in bringing the concept
that, with the exception of some nodular amyloidosis, the amyloid
substance is ‘‘keratinoid amyloid.’’ In order to outline how editorials
published in the JID (a painful task for editors and authors!) are useful,
I urge you to read or reread Hashimoto’s editorial in 1984 on
cutaneous amyloidoses [83]. It depicts how electron microscopy,
immunologic, and biochemical methods allowed the identification of
the source of amyloid in skin limited amyloidoses, i.e., the apoptotic
keratinocyte.
Maturing Clinical Research in ‘‘Major’’ Dermatoses Many
‘‘major’’ dermatoses fall into one of the sections covered by the other
associate editors, such as genetics, immunology, cell biology, etc.
They also fully pertain to clinical research because papers published in
the JID often drastically modified understanding and therapy of several
major diseases, thus having direct clinical impact. As examples of this
category, the report by Schlitz and Michel [84] on the induction of
acantholysis by the IgG fraction of pemphigus serum in human skin
in vitro and Bauer et al [85] on the role of skin collagenase in
dystrophic epidermolysis bullosa should be included. Atopic derma-
titis has not been covered in this review. This probably reflects the fear
and lazyness of the author when looking at the huge number of papers
published in the JID since 1938 on this condition. ‘‘We are still waiting
for the key paper, paving the way for significant progress in
pathophysiology and therapy. It seems we are still descriptive, even
when sophisticated biochemical and immunologic methods are used.
To stay on descriptive morphology, the paper by Mihm et al [86] has
become a classic, even if the authors state in the introduction ‘‘the
purpose of this presentation is to provide a brief description of normal
cutaneous histology as observed in 1 um-thick Epon embedded
sections and to describe the alterations which characterize atopic
eczema.’’
An interesting example of maturing clinical research is to look at a
succession of JID papers dealing with congenital ichthyoses. A
histologic study by Wells and Kerr [87] showed the distinct patterns
of autosomal dominant ichthyosis as compared to X linked lchthyosis.
Frost et al [88] reported the same year that excessive proliferation, as
shown by autoradiography, is a feature of lamellar ichthyosis and
‘‘epidermolytic hyperkeratosis,’’ whereas it is not found in ichthyosis
vulgaris. By grafting the skin of lamellar ichthyosis onto nude mice,
Briggaman and Wheeler [89] suggested that the defective gene in this
disease acts directly on the epidermis. Biochemical techniques
allowed Sybert et al [90] to observe that profilaggrin and filaggrin
are reduced in the epidermis of ichthyosis vulgaris, in which
keratohyahne granules are absent or reduced. We shall learn more
on ichthyoses by reading the JID in the near future (Fig 4).
I would like to close this section by referring to the last paper by a
gentleman of modern Dermatology, Dr. J.N. Gillian, who died while
the final draft of his manuscript was being prepared. This study [91],
an example of ‘‘clinical research’’ in Dermatology, is on the
prognostic significance of the lupus band test in uninvolved skin of
patients with lupus erythematosous. It is a 10-year longitudinal study
Figure 4. The best demonstration of the usefulness of the lupus band test in
identifying a subset of SLE patients with ‘‘more aggressive renal disease and
decreased long-term survival.’’ (From Davis BM, Gilliam JN: J Invest Dermatol
83:242–247, 1984)
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in 51 patients. It indicates that the test does have ‘‘predictive value in
that it identifies a subset of SLE patients with more aggressive renal
disease and significantly decreased long-term survival.’’
RETINOIDS IN THE JID
About sixty papers have been published in the JID on vitamin A and
retinoids; only three are within the 200 top cited papers. As one would
expect, more than 50% were published after 1980, whereas three
appeared in the 1940s, eight in the 1950s, seven in the 1960s, and
eight in the 1970s. It is beyond the scope of this review to comment on
all these papers. They are listed in Table IV under four headings.
Reports on therapeutic use of retinoids have been very few.
Although the observation was made in animals, the fact that
trichophyton verrucosum infection might be cured by systemic
administration of vitamin A (Table IV) is interesting. The author of
the present review is not aware of a trial of topical retinoids in human
dermatophytosis. Such a use of retinoids might increase their market
value, although not to the level of their use for skin aging.
The number of in vitro studies was not as high as expected (Table
IV) and the observations made herein are sometimes difficult to
integrate into the in vivo situation. Many important contributions on
the metabolism of retinoids in vivo appeared in the JID. Although none
is in the 200 top cited papers (possibly because they are recent), some
will remain key references, notably the series of papers from the
Uppsala group. The bulk of papers on retinoids dealt with in vivo
studies on the mode of action in the skin. Many of these have been
Table IV. Papers on Vitamin A and Retinoids in the JID
(Vol 1-87)a
Use for therapy
Systemic acqueous vitamin A for acne vulgaris 1949, 12:221
1950, 14:283
Cure of trichophyton verrucosum infection by systemic
vitamin A in cattle 1964, 42:173
Etretinate enhances PUVA 1978, 70:178b
In vitro studies
RA exert on mitogenic activity on post embryonal
epidermal cells 1973, 63:450
Vitamin A affects growth and differentiation in epidermal
outgrowth 1975, 64:19
Effects of RA on embryonic chick skin 1977, 69:463
Effects of several retinoids on embryonic chick skin 1979, 72:11
Effects of retinol in morphogenesis of mouse vibrissae 1978, 71:286
RA causes premature desquamation in keratinocytes
cultures 1982, 79:253
RA modulates fibroblast collagenase activity 1983, 81:162
RA increases expression of pemphigus antigen and
cytoplasmic expression of BP antigen 1984, 82:329
Structure activity of retinoids in chick embryo morphogenesis 1984, 83:105
Etretinate and RA modulate beta adremagic arenylate
cyclase response 1985, 85:324
Retinol modulates Langerhans cell markers and IL1
production 1985, 85:501
In vitro metabolism of isotretinoin by preputial glands 1985, 85:465
Studies on metabolism (in vivo)
Sex difference in vitamin A metabolism 1950, 15:409
Liver vitamin A in Darier’s disease 1954, 23:71
Percutaneous absorption of vitamin A 1958, 30:315
Percutaneous and oral absorption of vitamin A 1958, 31:575
and 577
Carotinoids in sebum after oral intake 1958, 31:599
Topical use of tritiated retinoic acid 1971, 55:249
Topical use of tritiated retinoic acid 1971, 57:323
Vitamin A metabolism in human skin 1982, 79:89
and 94
Milk intake increases etretinate absorption 1984, 82:636
UV irradiation reduces retinol in epidermis 1984, 83:401
Pharmacokinetics of topically applied retinoids 1985, 84:184
Biosynthesis of vitamin A2 from retinol 1985, 85:498
Table IV. Continued
Serum and skin concentrations of isotretinoin and
retinol during oral therapy for acne 1986, 86:384
In vivo studies on the mode of action
Mode of action of vitamin A (an historical forum) 1953, 21:421
Response of mouse skin to topical vitamin A 1956, 26:69
Response of mouse skin to topical vitamin A 1958, 31:313b
Biometric analysis of the effects of oral vitamin
A on human epidermis 1961, 37:459
Vitamin A deficiency reduces epidermal mitosis 1961, 37:469b
Topical RA affects hyperkeratinization 1967, 49:165
1970, 54:126
Topical RA increases mitotic indexes 1973, 59:228
Topical RA increases PGE, cAMP and cGMP 1976, 67:231
Ultrastructural study of the effect of topical RA 1979, 73:203
Isotretinoin induced inhibition of Hamster flank
organ is not an anti androgen effect 1980, 74:392
Etretinate, unlike isotretinoin does not affect
Hamster flank organ 1981, 76:68
Inhibition of UV induced carcinogenesis by RA 1981, 76:178
Oral administration of etretinate increases epidermal
cell proliferation in hairless mice 1981, 77:287
Topical RA increases epidermal transglutaminase 1982, 79:189
Freeze fracture study of the effect of etretinate on
psoriatic epidermis 1983, 80:174
Etretinate reduces urinary polyamines in psoriatic patients 1983, 80:181
Effect of etretinate on Langerhans cells 1983, 81:10
Etretinate reduces neutrophil chemotaxis 1983, 81:418
Cellular retinoid binding proteins in epidermis and
sebaceous glands 1984, 82:79
Topical retinoids effect on rhino mouse utricules 1984, 82:632
Topical and systemic effect on rhino mouse utricules 1984, 83:110
Topical RA inhibits S91 melanoma growth 1985, 85:89
Cellular RA binding protein in chick embryos skin 1985, 85:279
Cellular RA binding protein in normal human skin 1985, 85:460
Cellular RA binding protein increased in psoriatic plaques 1986, 86:42
Isotretinoin therapy changes cutaneous bacterial flora 1986, 86:390
Systemic etretin increases cellular RA binding protein in
human epidermis 1986, 76:122
Topical RA effect on dermal collagen and
glycosaminoglycans 1986, 87:663
aAlthough most of the papers are listed, it may be that some had escaped
the method of collecting the data.
bIndicates the paper is in the 200 top cited papers.
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made in human because systemic synthetic retinoids were used as
therapeutic agents. A historical ‘‘forum’’ followed the paper published
by Flesh in 1953 [92]. It is interesting that the last sentence of the
discussion, in which many prominent dermatologists of that time
participated, says ‘‘A strict distinction between the physiological and
the pharmacological effects of vitamin A may be impossible.’’ Table IV
lists most of the studies published since in the JID. Despite the
important message given in many of these reports, we still have no
answer to the question raised by Flesh and do not know how retinoids
work in human skin. It is hoped that the key paper on this issue will
soon appear in this Journal.
I deeply thank Christine Wasungfor the help in preparing the manuscript and handling the
weighty bound volumes of the journal, Dr. Denis Salomon and Conrad Hauserfor helpful
criticism, and Joseph McGuire for reviewing the English style.
REFERENCES
1. Baer RL, Sulzberger MB: Pyribenzamine in the treatment of itching
skin conditions. J Invest Dermatol 7:147–151, 1946
2. Perry DJ: The local use of Benadryl ointment. J Invest Dermatol
8–9:95–97,1947
3. Anderson HH: New surface active antibiotics. J Invest Dermatol
8–9:25–33, 1947
4. Miller JL, Slatkin MH, Johnson BA: Local use of Bacitracin. J Invest
Dermatol 10:179–188,1948
5. Wooldridge WE: The gamma isomer of hexachlorocyclohexane in the
treatment of scabies. J Invest Dermatol 10:363–366, 1948
6. Tyson TL: The effect of gelatin on fragile finger nails. J Invest Dermatol
14:323–325, 1950
7. Melton FM, Shelley WB: The effect of topical antipruritic therapy
on experimentally induced pruritus in man. J Invest Dermatol
15:325–333,1950
8. Witten VH: The effects of penicillin on certain hitherto incurable
dermatoses. J Invest Dermatol 16:193–200, 1951
9. Sulzberger MB, Sauer GC, Herrmann F, Baer RL, Milberg IL: Effects
of ACTH and cortisone on certain diseases and physiologic functions of
the skin: I. Effects of ACTH. J Invest Dermatol 16:323–337,1951
10. Brunner MJ, Riddell JM, Best WR: Cutaneous side effects of ACTH,
cortisone and pregnenolone therapy. J Invest Dermatol 16:205–210,
1951
11. Sulzberger MB, Witten VH: The effect of topically applied compound
F in selected dermatoses. J Invest Dermatol 19:101–102, 1952
12. Cramer JA, Lewis GM: Atabrine in the treatment of discoid lupus
erythematosus. J Invest Dermatol 19:393–395, 1952
13. Sawicky HH, Kanof NB, Silverberg MG, Braitman M, Kalish B:
Therapeutic assays of the skin and cancer unit of the New York
University Hospital. Assay VII. Quinacrine hydrochloride
(Atabrine hydrochloride for chronic discoid lupus erythematosus). J
Invest Dermatol 19:397–404, 1952
14. Wells GC: Treatment of chronic discoid lupus erythematosus with
Atabrine. J Invest Dermatol 19:405–407, 1952
15. KnoxJM, LambJH, Shelmire B, Morgan RJ: Light sensitive eruptions
treated with atabrine and chloroquine. J Invest Dermatol 19:11–16, 1952
16. Van de Erve J: Erythromycin therapy of acne vulgaris. J Invest Dermatol
23:67–69, 1954
17. Cornbleet T: Sulfone drugs in Duhring’s disease. Further experiences.
J Invest Dermatol 26:489–491, 1956
18. Knox JM, Guin J, Cockerell EG: Benzophenones. Ultraviolet light
absorbing agents. J Invest Dermatol 29:435–444, 1957
19. James APR: Intradermal triamcinolone acetonide in localized lesions.
J Invest Dermatol 34:175–176, 1960
20. Crounse RG: Human pharmacology of griseofulvin: the effect of fat
intake on gastrointestinal absorption. J Invest Dermatol 37:529–533,1961
21. Goldman L, Blaney DJ, Kindel DJ, Franke EK: Effect of the laser beam
on the skin. Preliminary report. J Invest Dermatol 40:121–122, 1963
22. Schlagel CA, Sanborn EC: The weights of topical preparations required
for total and partial body inunction. J Invest Dermatol 42:253–256, 1964
23. Thomas L: On warts. In: The Medusa and the snail. Penguin Books Ltd,
Harmondsworth, 1974, p 66
24. Clarke GHV: The charming of warts. J Invest Dermatol 45:15–21, 1965
25. Klein E, Stoll HL, Milgrom H, Case RW, Traenkle HL, Graham S, Laor Y,
Helm F: Tumors of the skin: IV. Double-blind study on effects of local
administration of anti-tumor agents in basal cell carcinoma. J Invest
Dermatol 44:351–353, 1965
26. Klein E, Stoll HL, Milgrom H, Traenkle HL, Case RW, Laor Y, Helm F,
Nadel RS: Tumors of the skin: V. Local administration of anti-tumor
agents to multiple superficial basal cell carcinomas. J Invest Dermatol
45:489–497, 1965
27. Mathews-Roth MM, Pathak MA, Parrish J, Fitzpatrick TB, Kass EH,
Toda K, Clemens W: A clinical trial of the effects of oral beta-carotene on
the responses of human skin to solar radiation. J Invest Dermatol
59:349–353, 1972
28. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL, and
28 participating investigators: Oral methoxsalen photochemotherapy for
the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol
68:328–335, 1977
29. Fritsch PO, Hbnigsmann H, Jaschke E, Wolff K: Augmentation of oral
methoxsalen-photochemotherapy with an oral retinoic acid derivative.
J Invest Dermatol 70:178–182, 1978
30. Bernstein JE, Swift RM, Soltani K, Lorincz AL: Inhibition of axon reflex
vasodilatation by topically applied capsaicin. J Invest Dermatol
76:394–395, 1981
31. Bernstein JE, Swift RM, Soltani K, Lorincz AL: Antipruritic effect of an
opiate antagonist, naloxone hydrochloride. J Invest Dermatol 78:82–83,
1982
32. Robins EJ, Breathnach AS, Bashin VP, Ethridge L, Nazzaro-Porro M,
Passi S, Picardo M: Effectiveness of azelaic acid as a depigmenting and
chemotherapeutic agent. J Invest Dermatol 87:293, 1986
33. Pathak MA, Wick MM: Effectiveness of azelaic acid as a depigmentation
and chemotherapeutic agent. Reply. J Invest Dermatol 87:294, 1986
34. Epstein S: Photoallergy and primary photosensitivity to sulfanilamide.
J Invest Dermatol 2:43–51, 1939
35. Shelley WB, Horvath PN: Experimental miliaria in man. III. Production
of miliaria rubra (prickly heat). J Invest Dermatol 14:193–204, 1950
36. Sidi E, Dobkevitch-Morrill S: The injection and ingestion test in
cross-sensitization to the para group. J Invest Dermatol 16:299–310,
1951
37. Epstein WL, Kligman AM: Transfer of allergic contact-type delayed
sensitivity in man. J Invest Dermatol 28:291–304, 1957
38. Baer RL, Michaelides P, Prestia AE: Failure to induce immune tolerance
to nitrogen mustard. Intravenous administration preceding topical use in
patients with psoriasis. J Invest Dermatol 58:1–3, 1972
39. Vilanova X, Casanovas M, Francmo J: Onychomycosis. An experimental
study. J Invest Dermatol 27:77–101, 1956
40. Arieli G, Alteras I, Feuerman EJ: Experimental inoculation of dermato-
phytes on psoriatic skin. J Invest Dermatol 72:33–34, 1979
41. Burke RC: Tinea versicolor: susceptibility factors and experimental
infection in human beings. J Invest Dermatol 36:389–401, 1961
42. Faergemann J: Experimental Tinea versicolor in rabbits and humans with
Pityrosporum orbiculare. J Invest Dermatol 72:326–329, 1979
43. Duncan WC, McBride ME, Knox JM: Experimental production of
infections in humans. J Invest Dermatol 54:319–323, 1970
44. Leyden JJ, Stewart R, Kligman AM: Experimental infections with group
A streptococci in humans. J Invest Dermatol 75:196–201, 1980
45. Soter NA, Lewis RA, Corey EJ, Austen KF: Local effects of synthetic
leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest
Dermatol 80:115–119, 1983
140S Saurat THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
46. Camp R, Jones RR, Brain S, Woollard P, Greaves M: Production of
intraepidermal microabscesses by topical application of Leukotriene B4.
J Invest Dermatol 82:202–204, 1984
47. Pinkus H: Examination of the epidermis by the strip method of removing
horny layers. I. Observations on thickness of the horny layer, and on
mitotic activity after stripping. J Invest Dermatol 16:383–386,1951
48. Pinkus H: Examination of the epidermis by the strip method. II. Biometric
data on regeneration of the human epidermis. J Invest Dermatol
19:431–446, 1952
49. Van Scott EJ, Reinertson RP, Steinmuller R: The growing hair roots on the
human scalp and morphologic changes therein following amethopterin
therapy. J Invest Dermatol 29:197–204, 1957
50. Kligman AM, Shelley WB: An investigation of the biology of the human
sebaceous gland. J Invest Dermatol 30:99–124, 1958
51. Strauss JS, Pochi PE: The quantitative gravimetric determination of sebum
production. J Invest Dermatol 36:293–298, 1961
52. Jones KK, Spencer MC, Sanchez SA: The estimation of the rate of
secretion of the sebum in man. J Invest Dermatol 17:213–226,1951
53. Burnham TK, Neblett TR, Fine G: The application of the fluorescent
antibody technic to the investigation of lupus erythematosus and various
dermatoses. J Invest Dermatol 41:451–456, 1963
54. Weinstein GD, Van Scott EJ: Autoradiographic analysis of turnover times
of normal and psoriatic epidermis. J Invest Dermatol 45:257–262, 1965
55. Blank IH, Miller OG: A method for the separation of the epidermis from
the dermis. J Invest Dermatol 15:9–10, 1950
56. Kiistala U, Mustakallio KK: Dermo-epidermal separation with suction.
Electron microscopy and histochemical study of initial events of
blistering on human skin. J Invest Dermatol 48:466–477, 1967
57. Kiistala U: Suction blister device for separation of viable epidermis from
dermis. J Invest Dermatol 50:129–137, 1968
58. Chorzelski TP, Beutner EH, Jablonska S, Blaszczyk M, Triftshauser C:
Immunofluorescence studies in the diagnosis of dermatitis herpetiformis
and its differentiation from bullous pemphigoid. J Invest Dermatol
56:373–380, 1971
59. Michel B, Milner Y, David K: Preservation of tissue-fixed immuno-
globulines in skin biopsies of patients with lupus erythematosus and
bullous diseases-preliminary report. J Invest Dermatol 59:449–452,1973
60. Gammon WR, Briggaman RA, Inman AO, Queen LL, Wheeler CE:
Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ
antibodies by indirect immunofluorescence on 1.0M sodium chloride-
separated skin. J Invest Dermatol 82:139–144, 1984
61. Holubar K, Wolff K, Konrad K, Beutner EH: Ultrastructural localization of
immunoglobulins in bullous pemphigoid skin. Employment of a new
peroxidase-antiperoxidase multistep method. J Invest Dermatol
64:220–227, 1975
62. Schaumburg-Lever G, Rule A, Schmidt-Ullrich B, Lever WF:
Ultra-structural localization of in vivo bound immunoglobulins in
bullous pemphigoid—a preliminary report. J Invest Dermatol 64:47–49,
1975
63. Edelson RL, Smith RW, Frank MM, Green IR: Identification of sub-
populations of mononuclear cells in cutaneous infiltrates. I. Differentia-
tion between B cells, T cells and histiocytes. J Invest Dermatol 61:82–89,
1973
64. Moll I, Moll R: Cells of extramammary Paget’s disease express
cytokeratins different from those of epidermal cells. J Invest Dermatol
84:3–8,1985
65. Heagerty AHM, Kennedy AR, Gunner DB, Eady RAJ: Rapid prenatal
diagnosis and exclusion of epidermolysis bullosa using novel antibody
probes. J Invest Dermatol 86:603–605, 1986
66. Holloway GA, Watkins DW: Laser doppler measurement of cutaneous
blood flow. J Invest Dermatol 69:306–309, 1977
67. Klemp P, Bojsen J: Local variation in cutaneous and subcutaneous blood
flow measured by CdTe(Cl) minidetectors in normal and psoriatic skin.
J Invest Dermatol 86:109–114, 1986
68. Sagher F, Cohen C, Schorr S: Concomitant bone changes in urticaria
pigmentosa. J Invest Dermatol 18:425–432, 1952
69. Convit J, Kerdel-Vegas F, Rodriguez G: Erythema dyschromicum
perstans. A hitherto undescribed skin disease. J Invest Dermatol
36:457–462, 1961
70. Soter NA, Austen KF, Gigli I: Urticaria and arthralgias as manifestations
of necrotizing angiitis (vasculitis). J Invest Dermatol 63:485–490, 1974
71. Sarkany I, Taplin D, Blank H: The etiology and treatment of erythrasma.
J Invest Dermatol 37:283–290, 1961
72. Cole GW, Wuepper KD: Isolation and partial characterization of a
keratinocyte proliferative factor produced by Streptococcus pyogenes
(Strain NY-5). J Invest Dermatol 71:219–223, 1978
73. Rasmussen EO, Wuepper KD: Purification and characterization of
Streptococcal proliferative factor. J Invest Dermatol 77:246–249, 1981
74. Bibel DJ, Aly R, Shinefield HR, Maibach HI. Strauss WG: Importance of
the keratinized epithelial cell in bacterial adherence. J Invest Dermatol
79:250–253, 1982
75. Ray TL, Digre Kb, Payne CD: Adherence of Candida species to human
epidermal corneocytes and buccal mucosal cells: correlation with
cutaneous pathogenicity. J Invest Dermatol 83:37–41, 1984
76. Ray TL, Wuepper KD: Activation of the alternative (Properdin) pathway
of complement by Candida albicans and related species. J Invest
Dermatol 67:700–703, 1976
77. Catterall MD, Ward ME, Jacobs P: A reappraisal of the role of
Pityrosporum orbiculare in pityriasis versicolor and the significance of
extracellular lipase. J Invest Dermatol 71:398–401, 1978
78. Marples RR, Downing DT, Kligman AM: Control of free fatty acids in
human surface lipids by corynebacterium acnes. J Invest Dermatol
56:127–131,1971
79. Epstein W, Kligman AM: The pathogenesis of milia and benign tumors of
the skin. J Invest Dermatol 26:1–11, 1956
80. Wilkin JK: Oral thermal-induced flushing in erythematotelangiectatic
rosacea. J Invest Dermatol 76:15–18, 1981
81. Thomas SE, Dykes PJ, Marks R: Plantar hyperkeratosis: a study of
callosities and normal plantar skin. J Invest Dermatol 85:394–397, 1985
82. Luderschmidt Ch, Plewig G: Circumscribed sebaceous gland hyperpla-
sia: autoradiographic and histoplanimetric studies. J Invest Dermatol
70:207–209, 1978
83. Hashimoto K: Progress on cutaneous amyloidoses. J Invest Dermatol
82:1–3,1984
84. Schiltz JR, Michel B: Production of epidermal acantholysis in normal
human skin in vitro by the IgG fraction from pemphigus serum. J Invest
Dermatol 67:254–260, 1976
85. Bauer EA, Gedde-Dahl T, Eisen AZ: The role of human skin collagenase
in epidermolysis bullosa. J Invest Dermatol 68:119–124, 1977
86. Mihm MC, Soter NA, Dvorak HF, Austen KF: The structure of normal
skin and the morphology of atopic eczema. J Invest Dermatol
67:305–312, 1976
87. Wells RS, Kerr CB: The histology of ichthyosis. J Invest Dermatol
46:530–535, 1966
88. Frost P, Weinstein GD, Van Scott EJ: The ichthyosiform dermatoses II.
Autoradiographic studies of epidermal proliferation. J Invest Dermatol
47:561–567, 1966
89. Briggaman RA, Wheeler CE: Lamellar ichthyosis: long-term graft studies
on congenitally athymic nude mice. J Invest Dermatol 67:567–572, 1976
90. Sybert VP, Dale BA, Holbrook KA: Ichthyosis vulgaris: identification of a
defect in synthesis of filaggrin correlated with an absence of keratohya-
line granules. J Invest Dermatol 84:191–194, 1985
91. Davis BM, Gilliam NJ: Prognostic significance of subepidermal
immune deposits in uninvolved skin of patients with systemic lupus
erythematosus: a 10-year longitudinal study. J Invest Dermatol
83:242–247, 1984
92. Flesch P: Studies on the mode of action of vitamin A. J Invest Dermatol
21:421–434, 1953
VOL. 92, NO. 4, SUPPLEMENT, APRIL 1989 50 YEARS OF CLINICAL RESEARCH IN THE JID 141S
